Free Trial
NASDAQ:MTVA

MetaVia (MTVA) Stock Price, News & Analysis

MetaVia logo
$0.66 -0.02 (-2.94%)
As of 12:04 PM Eastern

About MetaVia Stock (NASDAQ:MTVA)

Key Stats

Today's Range
$0.65
$0.70
50-Day Range
$0.65
$0.88
52-Week Range
$0.63
$5.16
Volume
113,084 shs
Average Volume
382,727 shs
Market Capitalization
$12.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

MetaVia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

MTVA MarketRank™: 

MetaVia scored higher than 41% of companies evaluated by MarketBeat, and ranked 704th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MetaVia has only been the subject of 2 research reports in the past 90 days.

  • Read more about MetaVia's stock forecast and price target.
  • Earnings Growth

    Earnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.

  • Price to Book Value per Share Ratio

    MetaVia has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MetaVia's valuation and earnings.
  • Short Interest

    There is no current short interest data available for MTVA.
  • Dividend Yield

    MetaVia does not currently pay a dividend.

  • Dividend Growth

    MetaVia does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTVA.
  • News Sentiment

    MetaVia has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.95 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MetaVia this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MetaVia insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of MetaVia is held by insiders.

  • Percentage Held by Institutions

    Only 1.37% of the stock of MetaVia is held by institutions.

  • Read more about MetaVia's insider trading history.
Receive MTVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter.

MTVA Stock News Headlines

Did you know you can now trade Bitcoin in your regular brokerage account?
We’re on the edge of what could be a massive parabolic move in Bitcoin that pushes the price past all-time highs… and over $100K. There was a little-known move by the NYSE in late 2021 that opened up a “loophole” for anyone with a regular brokerage account to take advantage of Bitcoin. Combined with a Trump presidency—who says he wants to be known as the first “Crypto President”—this creates an unprecedented opportunity.
See More Headlines

MTVA Stock Analysis - Frequently Asked Questions

MetaVia's stock was trading at $2.03 at the beginning of 2025. Since then, MTVA stock has decreased by 67.5% and is now trading at $0.66.
View the best growth stocks for 2025 here
.

MetaVia Inc. (NASDAQ:MTVA) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.21.

Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
6/27/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTVA
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$12.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,002.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.92 per share
Price / Book
0.74

Miscellaneous

Free Float
19,431,000
Market Cap
$13.32 million
Optionable
N/A
Beta
0.18
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:MTVA) was last updated on 6/27/2025 by MarketBeat.com Staff
From Our Partners